Companies
8-K ↗8-K ↗8-K ↗
BBIO
BridgeBio Pharma, Inc.
BridgeBio Pharma develops treatments for rare genetic and neurological diseases using genetic medicine approaches. The company has one approved product, acoramidis (marketed as Attruby in the U.S. and Beyonttra in the EU, UK, and Japan), and maintains a pipeline of candidates in development for conditions including achondroplasia, autosomal dominant hypocalcemia type 1, and limb-girdle muscular dystrophy type 2I/R9. BridgeBio is transitioning from a development-stage company to a commercial-stage company with the launch of its first approved product.
$71.11+85.38%1Y
BBIO · daily close · illustrative · 0 catalysts marked
Pipeline
UnknownIndication pending review
UnknownIndication pending review
UnknownIndication pending review
Catalyst Calendar
Past (3)
OCT 27
ReadoutBBP-418
“BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study”
OCT 29
ReadoutEncaleret
“BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1”
FEB 12
ReadoutInfigratinib
“BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia”